Trials
2 active
4 in total · 2 in the EU
What this is
- How it works
- Histamine-1 Receptor Antagonist FDA class
- Tested for
- Pruritus
- Main trialPhase 3
- “The main objective of the study is to assess efficacy and safety of dupilumab given up to 24 weeks in adults with CPUO. This is a master protocol which includes 2 parallel-treatment, double-blind, 2- arm Phase 3 staggered studies of similar design (Study A and Study B) in male and female participants aged 18 to 90 years with CPUO. Study B design was to be adapted based on the results of Study A. For both Study A and B, after an up-to-4-week screening period, participants with severe pruritus (worst-itch numerical rating scale \[WI-NRS ≥7) will enter a 4-week run-in period and will be…”In the company’s words, NCT05263206 on ClinicalTrials.gov
Other drugs for Pruritus
- SD-101TriSalus Life Sciences, Inc. · Phase 3
- DupilumabRegeneron · Sanofi · Phase 3
- LinerixibatGSK · Phase 3
- DeucravacitinibBristol Myers Squibb · Phase 3
- RitlecitinibPfizer · Phase 2
- VolixibatMirum Pharmaceuticals, Inc. · Phase 2
Coming up1
- 2 Jun 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 2 Jun 2027 | Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) | |
| Phase 4Completed | 25 Oct 2024 | A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme | |
| Phase 3Completed | 14 Mar 2023 | A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis | |
| Phase 2Authorised | not given | H1-antihistaminE treatment in combiNation with immunotHerapy in pAtieNts with advanced non small cell lung canCEr: A single- center phase II trial-ENHANCE |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026